# Almega PL (Nannochloropsis oculata extract)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/almega-pl
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Nannochloropsis oculata extract, Nannochloropsis oculata oil, Algal EPA oil, Polar lipid EPA, Microalgae omega-3, Plant-based EPA, Algae-derived omega-3, Vegan EPA supplement

## Overview

Almega PL is a standardized extract from Nannochloropsis oculata microalgae containing EPA and DHA omega-3 fatty acids. It supports [cardiovascular health](/ingredients/condition/heart-health) by improving lipid profiles and increasing omega-3 biomarkers through enhanced cell membrane incorporation.

## Health Benefits

• Increases Omega-3 Index by 15.5% (from 4.97% to 5.74%) after 12 weeks - based on RCT evidence • Reduces V[LDL cholesterol](/ingredients/condition/heart-health) by 25% - demonstrated in placebo-controlled trial • Lowers triglycerides by 14.2% in 6-month cohort study (n=292) • Decreases total cholesterol by 5% without raising LDL - multiple RCT evidence • Reduces remnant cholesterol by 25% - shown in randomized controlled trial

## Mechanism of Action

Almega PL delivers EPA and DHA that integrate into cell membrane phospholipids, particularly affecting red blood cell membranes. These omega-3s modulate [inflammatory pathway](/ingredients/condition/inflammation)s by inhibiting COX-2 and lipoxygenase enzymes while promoting specialized pro-resolving mediators. The algae-derived fatty acids also influence HMG-CoA reductase activity and VLDL synthesis in hepatic tissue.

## Clinical Summary

A 12-week randomized controlled trial demonstrated Almega PL increased omega-3 index from 4.97% to 5.74%, representing a 15.5% improvement. Placebo-controlled studies show 25% reduction in V[LDL cholesterol](/ingredients/condition/heart-health) levels. A 6-month cohort study with 292 participants found 14.2% triglyceride reduction and 5% total cholesterol decrease without elevating LDL. Evidence quality is moderate with consistent cardiovascular benefits across multiple endpoints.

## Nutritional Profile

Almega PL is a proprietary polar lipid-rich extract derived from Nannochloropsis oculata microalgae, standardized to deliver omega-3 fatty acids in a phospholipid and glycolipid matrix rather than the triglyceride form found in conventional fish oil. Key bioactive lipid fractions include EPA (eicosapentaenoic acid) as the dominant omega-3, primarily esterified to polar lipids (phospholipids and glycolipids), which confers enhanced bioavailability compared to triglyceride-bound EPA — studies suggest polar lipid-bound EPA absorption is meaningfully superior due to lymphatic and portal co-transport mechanisms. The extract contains approximately 8–12% total lipids by weight, with EPA representing a significant proportion of those fatty acids; exact EPA concentration per serving varies by formulation but typical doses in clinical studies range from 1–1.5g of the extract delivering meaningful EPA equivalents. Glycolipids (monogalactosyldiacylglycerol and digalactosyldiacylglycerol) and phospholipids (phosphatidylcholine, phosphatidylethanolamine) serve as the lipid carriers and contribute independently to the lipid-modifying effects. The microalgal matrix also contains chlorophyll pigments, carotenoids including zeaxanthin and beta-carotene at trace levels, and tocopherols (vitamin E) that provide intrinsic oxidative stability. Protein and carbohydrate content in the extract are minimal due to the lipid-extraction process. No significant dietary fiber, mineral, or water-soluble vitamin content has been documented in the isolated extract. Bioavailability is a key differentiator: polar lipid-bound EPA from Almega PL demonstrates faster incorporation into red blood cell membranes and plasma phospholipids compared to ethyl ester or triglyceride forms, consistent with the clinically observed 15.5% increase in Omega-3 Index at relatively modest doses.

## Dosage & Preparation

Clinically studied doses range from 900-1100 mg/day of Almega PL capsules (providing 225-275 mg EPA) for 3-6 months. The standardized extract contains >15% w/w polar lipids and >25% w/w EPA. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Almega PL is generally well-tolerated with mild gastrointestinal effects reported in <5% of users. May enhance anticoagulant effects of warfarin and increase bleeding risk when combined with antiplatelet medications. Contraindicated in individuals with fish or shellfish allergies despite algae source. Safety during pregnancy and lactation has not been established in clinical trials.

## Scientific Research

Clinical evidence includes a 12-week RCT (n=80, PMID: 32585854) showing significant improvements in Omega-3 Index and VLDL reduction, and a 6-month post-market cohort study (n=292, PMID: 38379539) demonstrating 14.2% triglyceride reduction. Multiple randomized controlled trials confirm consistent lipid-lowering effects without LDL elevation.

## Historical & Cultural Context

No evidence of traditional medicinal use was identified in the research. Almega PL represents a modern innovation in algal-derived supplements, developed as an alternative to fish oil for omega-3 supplementation.

## Synergistic Combinations

Vitamin E, CoQ10, Plant sterols, Astaxanthin, Vitamin D3

## Frequently Asked Questions

### How much does Almega PL increase omega-3 levels?

Clinical trials show Almega PL increases omega-3 index by 15.5% after 12 weeks of supplementation. This represents an improvement from 4.97% to 5.74% based on red blood cell membrane analysis.

### What is the typical dosage of Almega PL for cholesterol benefits?

Studies demonstrating cholesterol benefits used 1-2 grams daily of Almega PL extract. The 25% VLDL reduction was achieved with 1.5 grams daily over 12 weeks in placebo-controlled trials.

### Is Almega PL better than fish oil for omega-3s?

Almega PL provides similar EPA and DHA bioavailability to fish oil but offers advantages for vegetarians and those with fish allergies. Comparative studies show equivalent omega-3 index improvements between algae and fish sources.

### How long does it take to see cholesterol improvements with Almega PL?

Triglyceride reductions of 14.2% were observed within 8-12 weeks in clinical studies. VLDL cholesterol showed 25% improvement after 12 weeks of consistent supplementation with standardized dosing.

### Can Almega PL cause side effects or interact with medications?

Almega PL may cause mild digestive upset in less than 5% of users. It can enhance blood-thinning effects of warfarin and antiplatelet drugs, requiring medical supervision for patients on anticoagulant therapy.

### What clinical evidence supports the cholesterol-lowering benefits of Almega PL?

Almega PL has demonstrated significant cholesterol improvements in multiple randomized controlled trials, including a 25% reduction in VLDL cholesterol and a 5% decrease in total cholesterol without raising LDL levels. Additionally, a 6-month cohort study involving 292 participants showed a 14.2% reduction in triglycerides, while remnant cholesterol was reduced by 25% in controlled trials. These results establish Almega PL as a clinically validated option for dyslipidemia management.

### Who is the best candidate for Almega PL supplementation?

Almega PL is particularly beneficial for individuals with elevated triglycerides, high VLDL cholesterol, or suboptimal omega-3 status who seek a plant-based alternative to fish oil. People with Omega-3 Index levels below 5.8% may see meaningful improvements, as clinical data shows Almega PL increases the Omega-3 Index by 15.5% over 12 weeks. Those with dietary restrictions preventing fish consumption or individuals sensitive to fish-derived supplements are also ideal candidates.

### How does Almega PL compare to other plant-based omega-3 sources?

Unlike common plant-based omega-3 sources such as flaxseed or chia seed (which contain ALA requiring conversion), Almega PL is derived from Nannochloropsis oculata microalgae and delivers preformed EPA and DHA with documented clinical efficacy. The RCT evidence showing specific reductions in VLDL, triglycerides, and remnant cholesterol positions Almega PL above standard plant sources, making it more comparable to marine-derived omega-3s in terms of bioavailability and therapeutic outcomes.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*